Share: Facebook Twitter LinkedIn
Activity Provided By:

Paradigm Medical Communications, LLC

Treatment Selection for Patients With NSCLC With Low or Negative PD-L1 Expression

Access Activity

Overview / Abstract:

Target Audience

This activity has been designed to address the educational needs of medical oncologists. It may also be of benefit to other healthcare professionals (HCPs) who manage patients with non-small cell lung cancer (NSCLC).

Program Overview

The first-line treatment of advanced NSCLC without actionable mutations has undergone a dramatic change over the last 5 years, with the standard of care changing from chemotherapy to immune checkpoint inhibitor (ICI) monotherapy for select patients, to a variety of ICI-based combination regimens in addition to monotherapy. In addition, several more ICI-based regimens are currently under US Food and Drug Administration (FDA) review and are expected to be added to the armamentarium in the near future. Although these multiple first-line regimens provide oncology clinicians and their patients with options to select from, this also creates a major challenge: Remaining up to date on the latest clinical trial data for existing and emerging ICI-based regimens, as well as applying these changes to improve treatment selection.

Learning Objectives

Upon completion of this activity, participants should be better able to:

Evaluate the latest clinical trial data on immunotherapy-based combination regimens for the first-line treatment of NSCLC.
Select evidence-based first-line therapy for patients with advanced NSCLC, while considering patient- and treatment-related characteristics.
Agenda

Review of guideline recommendations for the use of ICI-based regimens
Case: Patient with newly diagnosed NSCLC with low/negative PD-L1 Expression
Role of combination regimens
Updates on clinical trial data
Treatment selection
Conclusion and faculty panel discussion

Expiration

Jan 31, 2022

Discipline(s)

Physician CME

Format

Online

Credits / Hours

0.5 AMA PRA Category 1 Credit(s)™

Accreditation

ACCME

Presenters / Authors / Faculty

Faculty

Matthew D. Hellmann, MD
Medical Oncologist
Memorial Sloan Kettering Cancer Center
New York, NY

Karen Reckamp, MD, MS
Director, Division of Medical Oncology
Associate Director, Clinical Research
Cedars-Sinai Cancer
Los Angeles, CA

Sponsors / Supporters / Grant Providers

Bristol-Myers Squibb Company and Merck & Co, Inc.

Keywords / Search Terms

Relias LLC Relias LLC., Free CME., NSCLC ,PD-L1 Expression Free CE CME

Access Activity

CORE Higher Education Group, CESearchEngine.com, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the CESearchEngine.com website or within our mobile apps.CORE Higher Education Group, CESearchEngine.com, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or within our mobile apps. For complete details, please read the CESearchEngine.com Terms of Service. Site Map